Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.

ABSTRACT:

Background

Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving.

Methods

We analysed time to progression, overall survival, and the mutational status of RAS, BRAF and nuclear p-IGF-1R expression by immunohistochemistry, in 470 metastatic CRC patients. The effect of IGF-1R activation and distribution was also assessed using cellular models of CRC and RNAi for functional validation.

Results

Nuclear IGF-1R increased in metastatic tumours compared to paired untreated pri

SUBMITTER: Codony-Servat J 

PROVIDER: S-EPMC5729466 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature